
FDA Requests Halt on Sarepta's Duchenne Gene Therapy Amid Safety Concerns
The FDA is expected to request Sarepta Therapeutics to halt shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, following safety concerns and patient deaths related to liver failure, which may lead to a market withdrawal amid ongoing safety investigations.
